| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/18/2010 | US20100040574 TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES |
| 02/18/2010 | US20100040556 Carrier nanoparticles and related compositions, methods and systems |
| 02/18/2010 | US20100040549 Composition for Targeted Drug Delivery and Controlled Release |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | US20100040539 Vector System |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | CA2734766A1 Compositions and methods for treatment during non-acute periods following cns neurological injury |
| 02/18/2010 | CA2734389A1 S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
| 02/18/2010 | CA2734185A1 Methods for using interferon gamma to absorb fluid from the subretinal space |
| 02/18/2010 | CA2734147A1 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 02/18/2010 | CA2734081A1 Combination therapy of hiv fusion/entry inhibitors targeting gp41 |
| 02/18/2010 | CA2733911A1 Use of gdf traps to increase red blood cell levels |
| 02/18/2010 | CA2733726A1 Novel protease inhibitors |
| 02/18/2010 | CA2733636A1 The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 02/18/2010 | CA2732892A1 Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
| 02/18/2010 | CA2732809A1 Aptamer inhibition of thrombus formation |
| 02/18/2010 | CA2731316A1 Pharmaceutical compositions |
| 02/17/2010 | EP2154251A1 Expression system of recombinant proteins with enhanced yield and immunogenicity |
| 02/17/2010 | EP2154244A1 Cell culture method using amino acid-enriched medium |
| 02/17/2010 | EP2154160A1 Hydroxyalkyl starch derivatives |
| 02/17/2010 | EP2153847A1 Gene sensitive to bone/joint disease and use thereof |
| 02/17/2010 | EP2153846A1 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immonostimulatory molecule |
| 02/17/2010 | EP2153844A1 Human hyaluronidases for axonal regrowth |
| 02/17/2010 | EP2153843A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/17/2010 | EP2153842A1 Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| 02/17/2010 | EP2153841A1 Vaccine comprising Amb 1 a peptides for use in the treatment of ragweed allergy |
| 02/17/2010 | EP2153840A1 Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin |
| 02/17/2010 | EP2153839A1 Composition for prevention and/or treatment of peptic ulcer |
| 02/17/2010 | EP2153820A1 Liposome and method for producing liposome |
| 02/17/2010 | EP2153736A1 Novel leukotriene receptor antagonist |
| 02/17/2010 | EP2152890A1 Multicistronic vectors and methods for their design |
| 02/17/2010 | EP2152881A2 Rumc peptides with antimicrobial activity |
| 02/17/2010 | EP2152867A1 Methods for preparing factor x, activated factor x, inactivated factor x and inactivated factor xa, and pharmaceutical compositions comprising same |
| 02/17/2010 | EP2152855A1 Recombinant protein production in avian ebx® cells |
| 02/17/2010 | EP2152743A2 Cross-linked collagen and uses thereof |
| 02/17/2010 | EP2152741A2 Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases |
| 02/17/2010 | EP2152740A1 Products for altering il-33 activity and methods therefor |
| 02/17/2010 | EP2152739A2 Mutants of interleukin-1 receptor antagonist and uses thereof |
| 02/17/2010 | EP2152737A2 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 02/17/2010 | EP2152736A1 Complement factor h-derived short consensus repeat-antibody constructs |
| 02/17/2010 | EP2152729A1 Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| 02/17/2010 | EP2152299A2 Pharmaceutical and/or cosmetic composition containing aconitase-activating active ingredients |
| 02/17/2010 | EP2152298A1 Modified nucleotide sequence encoding glucagon-like peptide-1 (glp-1) |
| 02/17/2010 | EP2152297A1 Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| 02/17/2010 | EP2152296A1 Injectable ready to use solutions comprising human chorionic gonadotropin |
| 02/17/2010 | EP2152295A1 Klotho protein and related compounds for the treatment and diagnosis of cancer |
| 02/17/2010 | EP2152294A2 Methods of modulating cellular homeostatic pathways and cellular survival |
| 02/17/2010 | EP2152293A1 Compositions for protein delivery and methods of use thereof |
| 02/17/2010 | EP2152292A1 Angiogenesis inhibitor comprising meteorin as an active ingredient |
| 02/17/2010 | EP2152291A1 Use of cyclosporines in the treatment of patients with intraocular lenses |
| 02/17/2010 | EP2152290A1 Methods for administering anti-il-5 antibodies |
| 02/17/2010 | EP2152289A1 Novel antimicrobial agents |
| 02/17/2010 | EP2152288A1 Reconstituted surfactants having improved properties |
| 02/17/2010 | EP2152287A2 Methods for treating and preventing gi syndrome and graft versus host disease |
| 02/17/2010 | EP2152245A2 Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| 02/17/2010 | EP2152243A2 Highly concentrated insulin solutions and compositions |
| 02/17/2010 | EP2152241A1 Method of delivering a protein into a cell |
| 02/17/2010 | EP2152234A1 Lyophilized pharmaceutical compositions and methods of making and using same |
| 02/17/2010 | EP2152233A1 High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant |
| 02/17/2010 | EP2152195A1 Peptide pharmaceutical for oral delivery |
| 02/17/2010 | EP2152099A1 Good tasting food product containing an agent for reducing carbohydrate uptake; and compositions containing such an agent |
| 02/17/2010 | EP2152085A1 Erythropoietin complementation or replacement |
| 02/17/2010 | EP1644504B1 Factor vii or viia gla domain variants |
| 02/17/2010 | EP1633774B1 Macrocyclic antagonists of the motilin receptor |
| 02/17/2010 | EP1578919B1 Endogenous retrovirus up-regulated in prostate cancer |
| 02/17/2010 | EP1536781B1 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| 02/17/2010 | EP1490013B1 Methods for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising hydroxyurea |
| 02/17/2010 | EP1263954B1 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/17/2010 | EP1240186B1 Improvements in or relating to immune responses to hiv |
| 02/17/2010 | EP1133560B1 Human parathyroid hormone modifications, preparation and use |
| 02/17/2010 | EP1117783B1 Gene expressed in prostate cancer |
| 02/17/2010 | CN101652145A Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| 02/17/2010 | CN101648010A Preparation for promoting fibroblasts to secrete extracellular matrix components and preparation method thereof |
| 02/17/2010 | CN101648009A Method for preparing cordycepin SOD medicinal granules |
| 02/17/2010 | CN101648008A Compound preparation used for joint care and preparation method thereof |
| 02/17/2010 | CN101648007A Pharmaceutical composition for treating ulcus cruris and preparation method thereof |
| 02/17/2010 | CN101648006A Medicinal composition for treating glaucoma and application thereof |
| 02/17/2010 | CN101648005A Medicinal composition for treating skin injury and ulcer and application thereof |
| 02/17/2010 | CN101648004A Medicinal composition for treating eye diseases and application thereof |
| 02/17/2010 | CN101648003A Medicinal composition for treating gynecological inflammation and application thereof |
| 02/17/2010 | CN101648002A Medicinal composition for treating skin injury and ulcer and application thereof |
| 02/17/2010 | CN101648001A Veterinary compound apramycin sulfate soluble powder and application thereof |
| 02/17/2010 | CN101648000A Application of cobrotoxin in preparing medicine for treating arthritis |
| 02/17/2010 | CN101647999A Application of sodium channel modulator BmK1 in building induction pain model |
| 02/17/2010 | CN101647998A New use of astragalus mongolicus lectin |
| 02/17/2010 | CN100590133C Growth hormone and serum albumni recombinant fusion protein |
| 02/17/2010 | CN100590131C Methods and compounds for the targeting of protein to exosomes |
| 02/17/2010 | CN100589845C Anti-neovasculature preparations for cancer |
| 02/17/2010 | CN100589841C Chinese medicine paste for curing oral cavity disease and preparation method thereof |
| 02/17/2010 | CN100589840C Application of compounds methionine enkephalin for preparing medicine for curing blood medulla hematopoietic system cancer |
| 02/17/2010 | CN100589839C Polypeptide and medicament composition containing polypeptide |
| 02/17/2010 | CN100589796C Highly efficient delivery of large therapeutic mass aerosol |
| 02/16/2010 | USRE41133 Glucagon-like peptide-1 crystals |
| 02/16/2010 | USRE41129 Cytokine zalpha11 ligand polynucleotides |
| 02/16/2010 | US7662951 RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| 02/16/2010 | US7662948 Antisense oligonucleotides against VR1 |
| 02/16/2010 | US7662944 Nucleotide sequences coding prolyl dipeptidyl peptidase for use as tool in identifying modulators for prevention and treatment of activity neoplasia, type II diabetes, cirrhosis, autoimmunity, graft rejection and HIV infection |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662932 Endothelial growth factor; isolated polypeptide; stimulate cell proliferation, neovascularization, vascular system permeability |
| 02/16/2010 | US7662931 immunoglobulin domain peptides having myostatin, erythropoietin or thrombopoietin peptides as an internal sequence, preferably in a loop region of the domain; antibodies |